These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31908769)

  • 41. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.
    Hutchens MP; Nakano T; Dunlap J; Traystman RJ; Hurn PD; Alkayed NJ
    Resuscitation; 2008 Jan; 76(1):89-94. PubMed ID: 17728042
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
    Xu X; Zhang XA; Wang DW
    Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A soluble epoxide hydrolase inhibitor--8-HUDE increases pulmonary vasoconstriction through inhibition of K(ATP) channels.
    Liu Y; Zhang J; Yu L; Cao F; Rao J; Li J; Jiang C; Falck JR; Jacobs ER; Zhu D
    Pulm Pharmacol Ther; 2012 Feb; 25(1):69-76. PubMed ID: 22155000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.
    McLellan GJ; Aktas Z; Hennes-Beean E; Kolb AW; Larsen IV; Schmitz EJ; Clausius HR; Yang J; Hwang SH; Morisseau C; Inceoglu B; Hammock BD; Brandt CR
    J Ocul Biol; 2016 Jan; 4(1):. PubMed ID: 28066796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis.
    Gurung AB; Mayengbam B; Bhattacharjee A
    Comput Biol Chem; 2018 Jun; 74():1-11. PubMed ID: 29522918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predominant role of vasoconstrictors over dilatators derived from arachidonic acid in hypoxic pulmonary vasoconstriction.
    Han Y; Yan G; Wang Q; Ma G; Tang C; Gu Y; Li L; Zhao J
    Mol Med Rep; 2013 Oct; 8(4):1263-71. PubMed ID: 23970347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vasodilatory responses of renal interlobular arteries to epoxyeicosatrienoic acids analog are not enhanced in Ren-2 transgenic hypertensive rats: evidence against a role of direct vascular effects of epoxyeicosatrienoic acids in progression of experimental heart failure.
    Sporková A; Husková Z; Škaroupková P; Rami Reddy N; Falck JR; Sadowski J; Červenka L
    Physiol Res; 2017 Mar; 66(1):29-39. PubMed ID: 27782740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
    Shahabi P; Siest G; Visvikis-siest S
    Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperhomocysteinemia dysregulates plasma levels of polyunsaturated fatty acids-derived eicosanoids.
    Al-Shabrawey M; Elmarakby A; Samra Y; Moustafa M; Looney SW; Maddipati KR; Tawfik A
    Life Res (Auckl); 2022 Apr; 5(2):. PubMed ID: 36341141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EETs reduces LPS-induced hyperpermeability by targeting GRP78 mediated Src activation and subsequent Rho/ROCK signaling pathway.
    Dong R; Hu D; Yang Y; Chen Z; Fu M; Wang DW; Xu X; Tu L
    Oncotarget; 2017 Aug; 8(31):50958-50971. PubMed ID: 28881620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.
    Rand AA; Barnych B; Morisseau C; Cajka T; Lee KSS; Panigrahy D; Hammock BD
    Proc Natl Acad Sci U S A; 2017 Apr; 114(17):4370-4375. PubMed ID: 28396419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart.
    Anwar-Mohamed A; El-Sherbeni AA; Kim SH; Althurwi HN; Zordoky BN; El-Kadi AO
    Xenobiotica; 2012 Dec; 42(12):1235-47. PubMed ID: 22680237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth.
    Oguro A; Sakamoto K; Suzuki S; Imaoka S
    Biol Pharm Bull; 2009 Dec; 32(12):1962-7. PubMed ID: 19952412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.
    Pillarisetti S; Khanna I
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):143-58. PubMed ID: 22280237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
    Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
    J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
    Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Roles of hypoxia-inducible factor-1α and its target genes in neonatal hypoxic pulmonary hypertension.
    Han CF; Li ZY; Li TH
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4167-4180. PubMed ID: 29028080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium.
    Ozaki M; Kawashima S; Yamashita T; Ohashi Y; Rikitake Y; Inoue N; Hirata KI; Hayashi Y; Itoh H; Yokoyama M
    Hypertension; 2001 Feb; 37(2):322-7. PubMed ID: 11230292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute mercury toxicity modulates cytochrome P450, soluble epoxide hydrolase and their associated arachidonic acid metabolites in C57Bl/6 mouse heart.
    Amara IE; Elshenawy OH; Abdelrady M; El-Kadi AO
    Toxicol Lett; 2014 Apr; 226(1):53-62. PubMed ID: 24472606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
    Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.